Incyte Corp (INCY)
66.44
-1.22 (-1.80%)
USD |
NASDAQ |
Sep 29, 14:21
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 14.78B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -1.49% |
| Valuation | |
| PE Ratio | 15.63 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 4.456 |
| Price to Book Value | 3.618 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 61.68% |
News
Headline
Wire
Time (ET)
Yahoo
09/27 11:31
MT Newswires
09/02 08:48
MT Newswires
08/26 10:42
Yahoo
08/26 10:00
Yahoo
08/24 08:00
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 11/02/2022* | -- | Results | Q3 2022 | -- | 0.72 | -- | |
| 11/02/2022* | 08:00 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 08/02/2022 | -- | Results | Q2 2022 | 1.01 | 0.75 | 35.50% | |
| 08/02/2022 | 08:00 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 05/03/2022 | -- | Results | Q1 2022 | 0.55 | 0.69 | -20.06% | |
| 05/03/2022 | 08:00 EST | Earnings Call | Q1 2022 | -- | -- | -- | |
| 02/08/2022 | -- | Results | Q4 2021 | 0.10 | 0.87 | -88.45% | |
| 02/08/2022 | 08:00 EST | Earnings Call | Q4 2021 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs. |
| URL | https://www.incyte.com |
| Investor Relations URL | https://investor.incyte.com/ |
| HQ State/Province | Delaware |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Mid Cap/Growth |
| Next Earnings Release | Nov. 02, 2022 (est.) |
| Last Earnings Release | Aug. 02, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of September 28, 2022.
Fundamentals
| Revenue (TTM) | 3.320B |
| Total Expenses (TTM) | 2.589B |
| Net Income (TTM) | 945.01M |
| Total Assets (Quarterly) | 5.319B |
| Total Liabilities (Quarterly) | 1.234B |
| Shareholders Equity (Quarterly) | 4.085B |
| Cash from Operations (TTM) | 760.35M |
| Cash from Investing (TTM) | -128.03M |
| Cash from Financing (TTM) | 5.659M |
Ratings
Profile
Edit
| Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs. |
| URL | https://www.incyte.com |
| Investor Relations URL | https://investor.incyte.com/ |
| HQ State/Province | Delaware |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Mid Cap/Growth |
| Next Earnings Release | Nov. 02, 2022 (est.) |
| Last Earnings Release | Aug. 02, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Top Fund Holders
| Symbol | Dollars Invested | % Weight |
|---|---|---|
| FBT | 37.49M USD | 2.93% |
| ARKG | 67.40M USD | 2.92% |
| RBF5407 | 220.82M USD | 2.60% |
| RBF1370 | 48.63M USD | 2.58% |
| RBF5477 | 34.10M USD | 2.32% |
| RBF1045 | 32.52M USD | 2.28% |
| TDB3016 | 22.08M USD | 1.71% |
| SPGP | 20.55M USD | 1.69% |
| IBB | 111.57M USD | 1.53% |
| VGHCX | 683.76M USD | 1.51% |
| XBI | 68.84M USD | 1.04% |
| XT | 19.71M USD | 0.73% |
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Morningstar | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| INCY Tweets |